Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis — End of the road?

Abstract

A B S T R A C TAn estimated 1.8 billion people worldwide have a latent tuberculosis infection (LTBI), with wide variations in LTBI rates across countries. LTBI can be due to infection with either drug-sensitive or drugresistant Mycobacterium tuberculosis (Mtb) strains. Accurate data on the prevalence of LTBI due to multidrug-resistant (MDR) Mtb strains are unavailable, since the strains cannot be isolated for resistance testing. There are no 'gold standard' tests for accurately diagnosing LTBI. Only three tests are currently available and approved by the World Health Organization (WHO) for the diagnosis of LTBI: the now outdated tuberculin skin test (TST), developed a century year ago, and the two interferon-gamma release assays (IGRAs) developed and rolled out over the past decade, the QuantiFERON (Qiagen, Germany) and T-SPOT.TB (Oxford Immunotec, United Kingdom) tests. These latter tests are not ideal due to issues of sensitivity, specificity, inability to distinguish infection with MDR-Mtb strains, and high costs. Achieving the WHO End TB Strategy target of an 80% reduction in global TB incidence by 2030 will require a major reduction in the number of persons with LTBI progressing to active TB disease. Critical to this will be the development of new diagnostic tests that are better than currently available LTBI tests at predicting who is at risk of progression to active TB disease. The diagnostic product development portfolio for LTBI appears to have reached the end of the road. Every attempt to make optimal use of currently available IGRAs using WHO LTBI guidelines for LTBI testing and treatment must be made to achieve WHO End TB strategy targets.

Cumulative Signaling Through NOD-2 and TLR-4 Eliminates the Mycobacterium Tuberculosis Concealed Inside the Mesenchymal Stem Cells

“…Tuberculosis (TB) is the cause of 2 million deaths each year and an estimated 1.8 billion people with latent disease worldwide ( Mwaba et al., 2020 ). It is one of the top 10 diseases in terms of high morbidity and mortality worldwide ( Herbert et al., 2014 ).…”

Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics

“…The WHO aims to eradicate TB completely by the year 2030 ( 162 ) – an ambitious task. In order to achieve this, it is necessary to identify those living with latent TB, and to neutralize the threat before they become infectious ( 45 ). Identifying specific markers peculiar to patients with latent TB would be beneficial to tackling this challenge.…”

“…Latent TB can be detected only by carrying out tests such as the tuberculin skin test, interferon-gamma (IFN-γ) release assays, or the more recently developed QuantiFERON (Qiagen, Germany) and T.SPOT (Oxford Immunotec, UK) tests. Since these tests measure the resulting immune response in vivo or in vitro only, they cannot differentiate latent TB from resolved infection or active TB ( 43 – 45 ).…”

Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus

“…However, none of the tests can distinguish between subjects with latent tuberculosis and active tuberculosis. Nor can those subjects with a higher risk of developing active disease be identified ( Mwaba et al., 2020 ).…”